This site is intended for Healthcare professionals only.
×

Valeo Pharma and Zambon announces the approval of Onstryv for treatment of Parkinsons disease


Valeo Pharma and Zambon announces the approval of Onstryv for treatment of Parkinsons disease

There is a growing need for new treatments to manage Parkinson’s Disease and Onstryv provides an important option for patients that require better control of their symptoms.

France: Zambon an international pharmaceutical company and Valeo Pharma Inc., a speciality pharmaceutical company in order to commercialize innovative prescription products in Canada, recently announced the approval of Onstryv(safinamide) for the treatment of Parkinson’s Disease in Canada.

Under the terms of the agreement with Zambon, Valeo Pharma is responsible for all regulatory, quality, sales and marketing, and distribution activities in Canada.

“There is a growing need for new treatments to manage Parkinson’s Disease and Onstryv provides an important option for patients that require better control of their symptoms. We look forward to launching the first new oral treatment for Parkinson’s Disease in over a decade to Canadian patients in need of a new therapeutic choice,” said Steve Saviuk, Chief Executive Officer of Valeo.

Valeo Pharma expects the Canadian launch of safinamide to occur during the first half of 2019.

Roberto Tascione, CEO of Zambon said “The approval of safinamide in Canada is a step forward for patients who need new treatment options for Parkinson’s Disease. Our mission is to make this medication available to as many PD patients worldwide as possible.”

Parkinson’s Disease is a progressive neurological disease involving the loss of dopamine-producing neurons in the brain. While tremors are the best-known symptom, Parkinson’s Disease also causes slowed movement, rigid muscles, impaired posture and balance, and speech and writing difficulties. An estimated 100,000 Canadians are affected and the number of patients is expected to grow significantly over the next thirty years as the population continues to age.

Also Read: Fighting Parkinsons: Medica Hospital to launch new treatment in eastern India



Source: self
0 comment(s) on Valeo Pharma and Zambon announces the approval of Onstryv for treatment of Parkinsons disease

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted